Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the drug Plerixafor (Mozobil) can lead to
clinically relevant efflux of CD117+ stem cells from the bone marrow to the peripheral blood
of normal controls and patients awaiting lung transplantation. The investigator's hypothesis
is that Plerixafor (Mozobil) will lead to significant mobilization of CD117+ stem cells to
the peripheral blood.